Mergers & Acquisitions ·
Regeneron signs Sixth Amendment with Sanofi for $1B upfront plus up to $7B in milestones
REGNRegeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals entered into a Sixth Amendment to its Amended and Restated License and Collaboration Agreement with Sanofi. The deal establishes a co-development and co-commercialization partnership for four new long-acting antibodies targeting IL-13, IL-4, IL-4Rα, and IL-4xIL-13. Sanofi will pay an upfront fee of $1.0 billion to Regeneron, with potential additional payments of up to $7.0 billion upon achievement of development, regulatory, and commercial milestones. Profits from the new products will be shared equally between the parties. Concurrently, Regeneron agreed to dismiss its lawsuit against Sanofi regarding audit rights and information access for Dupixent. The filing also notes an expected acquired in-process research and development charge of approximately $22 million for the third quarter 2026. Regeneron is a biotechnology company focused on discovering, developing, and commercializing medicines for serious diseases.